NCT05525182 is a Phase 2, PHASE3 clinical trial of ES16001 40 mg in COVID-19, sponsored by Genencell Co. Ltd..

Who is sponsoring NCT05525182?

NCT05525182 is sponsored by Genencell Co. Ltd..

What drugs are being tested in NCT05525182?

Interventions in NCT05525182: ES16001 40 mg, ES16001 80 mg, ES16001 160 mg, Placebo.

Is NCT05525182 still recruiting?

NCT05525182 is currently status unknown. Last updated 22 February 2023.

Last reviewed 2023-02-22 · How we verify

NCT05525182

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of ES16001 in Patients With COVID-19

Status unknown Phase 2, PHASE3 Last updated 22 February 2023

What this trial tests

Phase 2, PHASE3 trial testing ES16001 40 mg in COVID-19 in 706 participants. Status unknown.

Timeline

5 July 2021

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Genencell Co. Ltd.
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	706
Start date	5 July 2021
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	3 locations across South Korea

Drugs / interventions tested

ES16001 40 mg — full drug profile →
ES16001 80 mg — full drug profile →
ES16001 160 mg — full drug profile →
Placebo

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Genencell Co. Ltd. — full company profile →

Who can join

19 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is phase II/III, randomized, parallel-group, double-blind, placebo-controlled study. Patients must be at least 19 years of age (or according to the legal age for adult in each country) with confirmed mild or moderate COVID-19 tested positive with a real time reverse transcription polymerase chain reaction (RT-PCR) analysis of rhinopharynx samples. RT-PCR analysis of rhinopharynx samples must be \<4 days old prior to the study enrolment

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05525182 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Genencell Co. Ltd.
Last refreshed: 22 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05525182.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing